lopinavir has been researched along with Koch's Disease in 29 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (10.34) | 29.6817 |
| 2010's | 15 (51.72) | 24.3611 |
| 2020's | 11 (37.93) | 2.80 |
| Authors | Studies |
|---|---|
| Jacobs, BA; Mtshali, S | 1 |
| Avihingsanon, A; Chaivichacharn, P; Gatechompol, S; Punyawudho, B; Ubolyam, S | 1 |
| Chabala, C; Choo, L; Chungu, C; Crook, A; Gibb, D; Kapasa, M; LeBeau, K; Lungu, J; McIlleron, H; Mulenga, V; Tembo, CH; Turkova, A; Weisner, L; Zimba, K; Zyambo, K | 1 |
| Aarnoutse, R; Chabala, C; Cotton, MF; Denti, P; Galileya, LT; Gibb, D; Hesseling, A; Lee, J; McIlleron, H; Njahira Mukui, I; Rabie, H; Turkova, A; Wasmann, RE; Zar, H | 1 |
| Alffenaar, JW; Andréjak, C; Bachez, P; Bart, PA; Belilovski, E; Blanc, FX; Borisov, S; Cardoso-Landivar, J; Centis, R; Codecasa, LR; D'Ambrosio, L; Dominguez-Castellano, A; Dourmane, S; Fréchet Jachym, M; Froissart, A; García-García, JM; Giacomet, V; Goletti, D; Grard, S; Gualano, G; Izadifar, A; Le Du, D; Luiza De Souza-Galvão, M; Marín Royo, M; Mazza-Stalder, J; Migliori, GB; Motta, I; Ong, CWM; Palmieri, F; Rivière, F; Rodrigo, T; Sánchez-Montalvá, A; Saporiti, M; Scarpellini, P; Schlemmer, F; Silva, DR; Sotgiu, G; Spanevello, A; Sumarokova, E; Tabernero, E; Tadolini, M; Tambyah, PA; Tiberi, S; Torre, A; Visca, D; Zabaleta Murguiondo, M | 1 |
| Cisse, K; Compaoré, TR; Diagbouga, S; Kouanda, S; Matteelli, A; Ouedraogo, HG; Regazzi, M; Roggi, A; Sangare, L; Simporé, J; Sulis, G; Tarnagda, G; Villani, P | 1 |
| Aarnoutse, RE; Burger, DM; Colbers, A; Dooley, KE; Jacobs, TG; McIlleron, H; Musiime, V; Rojo, P; Svensson, EM; Turkova, A | 1 |
| Agbaji, O; Darin, KM; Ejeliogu, E; Imade, G; Kanki, PJ; McIlleron, HM; Odaibo, G; Oguche, S; Ogunbosi, BO; Okonkwo, P; Oladokun, R; Olaleye, D; Rawizza, HE; Scarsi, KK; Wiesner, L | 1 |
| Cohn, SE; Denti, P; Dooley, KE; Firnhaber, C; Francis, J; Godfrey, C; Kendall, MA; McIlleron, H; Mngqibisa, R; Wu, X | 1 |
| Benson, CA; Cardoso, SW; Fletcher, CV; Ive, P; Kendall, MA; Lalloo, U; Podany, AT; Wu, X | 1 |
| Castelnuovo, B; Haguma, P; Kalibbala, D; Kirenga, B; Muddu, M; Mulindwa, F; Semitala, FC | 1 |
| McIlleron, H; Rabie, H; Rawizza, H; Van Rie, A; Wiesner, L; Winckler, J; Zar, H; Zuidewind, P | 1 |
| Akanmu, S; Brown, B; Chang, C; Darin, KM; David, N; Kanki, PJ; Ogunbosi, B; Okonkwo, P; Oladokun, R; Olaitan, O; Rawizza, HE; Scarsi, KK | 1 |
| Decloedt, EH; Denti, P; Karlsson, MO; McIlleron, H; Ren, Y; Zhang, C | 1 |
| Barrail-Tran, A; Borand, L; Connolly, C; Duc, NH; Dung, NH; Harries, AD; Lagarde, D; Lan, NN; Lan, NT; Laureillard, D; Lien, TT; Lienhardt, C; Pym, A; Quillet, C; Taburet, AM; Thu, NT | 1 |
| Chelin, N; Cohen, S; Gandhi, RT; Murphy, RA; Sunpath, H; Tennant, I; Winternheimer, P | 1 |
| Dooley, KE; Karlsson, MO; Svensson, EM | 1 |
| Gous, H; Kellermann, T; Kindra, G; McIlleron, H; Moultrie, H; Sawry, S; Van Rie, A; Wiesner, L | 1 |
| Connolly, C; Harries, A; Kellerman, T; Lienhardt, C; McIlleron, H; Naiker, S; Pym, A; Reddy, T; Wiesner, L | 1 |
| Fairlie, L; Link-Gelles, R; Madhi, S; Mahomed, N; Moultrie, H; Murdoch, D; Sawry, S; Van Rie, A; Verwey, C | 1 |
| Avenant, T; du Plessis, NM; Feucht, UD; Melikian, G; Rossouw, TM; Thomas, W; van Dyk, G | 1 |
| Khachi, H; Ladenheim, D; O'Connell, R; Orkin, C | 1 |
| Ashkin, D; Boulanger, C; Espinoza, LA; Farrell, K; Graham, JJ; Hollender, E; Maasen, D; Peloquin, CA; Rivero, RO; Stambaugh, JJ; Symes, S | 1 |
| Harinath, BC; Kamble, PD; Majumdar, A; Wankhade, G | 1 |
| Cotton, M; Eley, B; Fairlie, L; Maartens, G; McIlleron, H; Merry, C; Meyers, T; Nuttall, J; Rabie, H; Ren, Y; Smith, PJ | 1 |
| Bango, F; Decloedt, EH; Maartens, G; McIlleron, H; Merry, C; Smith, P | 1 |
| Apostoli, A; Bigoni, S; Calabresi, A; Carvalho, AC; Cusato, M; Dal Zoppo, S; El-Hamad, I; Marcantoni, C; Matteelli, A; Regazzi, M; Villani, P | 1 |
| Gandhi, RT; Kuritzkes, DR; Marconi, VC; Murphy, RA; Sunpath, H | 1 |
| Egbers, C; Eley, BS; Maartens, G; McIlleron, HM; Meyers, TM; Nuttall, JJ; Ren, Y; Smith, PJ | 1 |
1 review(s) available for lopinavir and Koch's Disease
| Article | Year |
|---|---|
Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review.
Topics: Anti-HIV Agents; Child; Child, Preschool; Coinfection; HIV Infections; Humans; Lopinavir; Pharmaceutical Preparations; Tuberculosis | 2020 |
7 trial(s) available for lopinavir and Koch's Disease
| Article | Year |
|---|---|
Safety and Pharmacokinetics of Double-Dose Lopinavir/Ritonavir + Rifampin Versus Lopinavir/Ritonavir + Daily Rifabutin for Treatment of Human Immunodeficiency Virus-Tuberculosis Coinfection.
Topics: Adult; Anti-HIV Agents; Coinfection; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Rifabutin; Rifampin; Ritonavir; Tuberculosis | 2021 |
Model-based evaluation of the pharmacokinetic differences between adults and children for lopinavir and ritonavir in combination with rifampicin.
Topics: Adult; Age Factors; Anti-HIV Agents; Antitubercular Agents; Biological Availability; Child, Preschool; Cohort Studies; Drug Interactions; Female; Half-Life; HIV Infections; Humans; Infant; Lopinavir; Male; Middle Aged; Models, Biological; Nonlinear Dynamics; Rifampin; Ritonavir; Tuberculosis | 2013 |
Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam.
Topics: Adult; Antibiotics, Antitubercular; Area Under Curve; Asian People; Biological Availability; Chemical and Drug Induced Liver Injury; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Rifabutin; Ritonavir; Treatment Outcome; Tuberculosis; Vietnam | 2014 |
Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Diarylquinolines; Drug Combinations; Drug Interactions; Female; HIV Infections; HIV-1; Humans; Lopinavir; Male; Middle Aged; Mycobacterium tuberculosis; Nevirapine; Ritonavir; Tuberculosis; Young Adult | 2014 |
Pharmacokinetics and safety of rifabutin in young HIV-infected children receiving rifabutin and lopinavir/ritonavir.
Topics: Antiretroviral Therapy, Highly Active; Antitubercular Agents; Area Under Curve; Child, Preschool; Coinfection; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Lopinavir; Male; Rifabutin; Ritonavir; Treatment Outcome; Tuberculosis | 2015 |
Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antibiotics, Antitubercular; Black People; Coinfection; Cross-Over Studies; Drug Therapy, Combination; Female; HIV Infections; Humans; Isoniazid; Lamivudine; Lopinavir; Male; Neutropenia; Rifabutin; South Africa; Stavudine; Tuberculosis; Uveitis | 2014 |
Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis.
Topics: Adult; Antibiotics, Antitubercular; Antiviral Agents; Drug Interactions; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Pyrimidinones; Rifabutin; Ritonavir; Tuberculosis | 2009 |
21 other study(ies) available for lopinavir and Koch's Disease
| Article | Year |
|---|---|
A Comparative Analysis of Physiologically Based Pharmacokinetic Models for Human Immunodeficiency Virus and Tuberculosis Infections.
Topics: Anti-Retroviral Agents; HIV; HIV Infections; Humans; Latent Tuberculosis; Lopinavir; Models, Biological; Rifampin; Ritonavir; Tuberculosis | 2022 |
Dose optimization with population pharmacokinetics of ritonavir-boosted lopinavir for Thai people living with HIV with and without active tuberculosis.
Topics: Anti-HIV Agents; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Rifampin; Ritonavir; Thailand; Tuberculosis | 2022 |
Inadequate Lopinavir Concentrations With Modified 8-Hourly Lopinavir/Ritonavir 4:1 Dosing During Rifampicin-based Tuberculosis Treatment in Children Living With HIV.
Topics: Anti-HIV Agents; Antitubercular Agents; Child; Child, Preschool; Drug Therapy, Combination; HIV Infections; Humans; Infant; Lopinavir; Rifampin; Ritonavir; Tuberculosis | 2023 |
Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis.
Topics: Adolescent; Adult; Antitubercular Agents; Child; Child, Preschool; Female; HIV; HIV Infections; Humans; Infant; Infant, Newborn; Isoniazid; Lopinavir; Male; Pyrazinamide; Rifampin; Ritonavir; Tuberculosis | 2023 |
Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases.
Topics: Adult; Aged; Antitubercular Agents; Antiviral Agents; Azithromycin; Betacoronavirus; Clinical Laboratory Techniques; Cohort Studies; Coinfection; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; Drug Combinations; Emigrants and Immigrants; Female; Humans; Hydroxychloroquine; Lopinavir; Lung; Male; Middle Aged; Mortality; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2; Tomography, X-Ray Computed; Tuberculosis; Tuberculosis, Pulmonary | 2020 |
Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Antibiotics, Antitubercular; Burkina Faso; Chromatography, High Pressure Liquid; Coinfection; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Protease Inhibitors; Humans; Lopinavir; Male; Microbial Sensitivity Tests; Pilot Projects; Random Allocation; Rifabutin; Ritonavir; Tandem Mass Spectrometry; Tuberculosis | 2020 |
Rifabutin pharmacokinetics and safety among TB/HIV-coinfected children receiving lopinavir/ritonavir-containing second-line ART.
Topics: Adolescent; Adult; Child; Coinfection; HIV Infections; Humans; Lopinavir; Rifabutin; Ritonavir; Tuberculosis | 2021 |
A Semimechanistic Pharmacokinetic Model for Depot Medroxyprogesterone Acetate and Drug-Drug Interactions With Antiretroviral and Antituberculosis Treatment.
Topics: Alkynes; Anti-Retroviral Agents; Antitubercular Agents; Benzoxazines; Contraceptive Agents, Hormonal; Contraceptive Effectiveness; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Delayed-Action Preparations; Drug Administration Schedule; Drug Combinations; Drug Interactions; Female; HIV Infections; Humans; Isoniazid; Lopinavir; Medroxyprogesterone Acetate; Nelfinavir; Rifampin; Ritonavir; Tuberculosis | 2021 |
Adoption of evidence-informed guidelines in prescribing protease inhibitors for HIV-Tuberculosis co-infected patients on rifampicin and effects on HIV treatment outcomes in Uganda.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Coinfection; Drug Therapy, Combination; Female; Guidelines as Topic; HIV Infections; HIV Protease Inhibitors; Humans; Inappropriate Prescribing; Lopinavir; Middle Aged; Protease Inhibitors; Rifampin; Ritonavir; Treatment Outcome; Tuberculosis; Uganda; Young Adult | 2021 |
Pharmacokinetics of adjusted-dose 8-hourly lopinavir/ritonavir in HIV-infected children co-treated with rifampicin.
Topics: Alanine Transaminase; Anti-HIV Agents; Antibiotics, Antitubercular; Child; Child, Preschool; Drug Combinations; Female; HIV Infections; Humans; Infant; Infant, Newborn; Lopinavir; Male; Plasma; Prospective Studies; Rifampin; Ritonavir; Treatment Outcome; Tuberculosis | 2019 |
Safety and efficacy of rifabutin among HIV/TB-coinfected children on lopinavir/ritonavir-based ART.
Topics: Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Biomarkers; Coinfection; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Lopinavir; Male; Retrospective Studies; Rifabutin; Ritonavir; Treatment Outcome; Tuberculosis | 2019 |
Double-dose lopinavir-ritonavir in combination with rifampicin-based anti-tuberculosis treatment in South Africa.
Topics: Adult; Antibiotics, Antitubercular; Coinfection; Drug Combinations; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Male; Middle Aged; Retrospective Studies; Rifampin; Ritonavir; South Africa; Treatment Outcome; Tuberculosis; Viral Load; Young Adult | 2014 |
Paradoxical tuberculosis-associated immune reconstitution inflammatory syndrome in children.
Topics: Antiretroviral Therapy, Highly Active; Antitubercular Agents; Child; Child, Preschool; Cohort Studies; Female; HIV Infections; HIV Protease Inhibitors; Humans; Immune Reconstitution Inflammatory Syndrome; Infant; Infant, Newborn; Lopinavir; Male; Prospective Studies; Ritonavir; South Africa; Tuberculosis; Tuberculosis, Lymph Node; Tuberculosis, Pulmonary | 2016 |
Factors Associated with the Development of Drug Resistance Mutations in HIV-1 Infected Children Failing Protease Inhibitor-Based Antiretroviral Therapy in South Africa.
Topics: Antiretroviral Therapy, Highly Active; Coinfection; Drug Resistance, Viral; Gene Frequency; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Host-Pathogen Interactions; Humans; Infant; Logistic Models; Lopinavir; Malnutrition; Mutation; Retrospective Studies; Risk Factors; Ritonavir; Time Factors; Tuberculosis | 2015 |
Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Female; HIV Infections; Humans; Lopinavir; Male; Pyrimidinones; Rifabutin; Ritonavir; Serum; Tuberculosis; Young Adult | 2009 |
Effect of HIV protease inhibitors and Orlistat on mycobacterial ES-31 serine protease, a potential drug target in Mycobacterium tuberculosis.
Topics: Antigens, Bacterial; Bacterial Proteins; Enzyme-Linked Immunosorbent Assay; HIV Protease Inhibitors; Humans; Lactones; Lopinavir; Mycobacterium tuberculosis; Orlistat; Pyrimidinones; Ritonavir; Serine Endopeptidases; Tuberculosis | 2011 |
Lopinavir exposure is insufficient in children given double doses of lopinavir/ritonavir during rifampicin-based treatment for tuberculosis.
Topics: Anti-HIV Agents; Antitubercular Agents; Child, Preschool; Drug Interactions; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Infant; Lopinavir; Male; Pyrimidinones; Rifampin; Ritonavir; South Africa; Treatment Outcome; Tuberculosis | 2011 |
The safety, effectiveness and concentrations of adjusted lopinavir/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Coinfection; Drug Interactions; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Rifampin; Ritonavir; Tuberculosis | 2012 |
Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy.
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Chromatography, High Pressure Liquid; Drug Interactions; Female; HIV Infections; Humans; Lopinavir; Male; Middle Aged; Plasma; Rifabutin; Ritonavir; Tuberculosis | 2012 |
Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa.
Topics: Adolescent; Adult; Anti-HIV Agents; Antibiotics, Antitubercular; Child; Coinfection; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Kaplan-Meier Estimate; Lopinavir; Male; Middle Aged; Retrospective Studies; Rifampin; Ritonavir; South Africa; Time Factors; Tuberculosis; Young Adult | 2012 |
Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis.
Topics: Antibiotics, Antitubercular; Child, Preschool; Drug Interactions; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lopinavir; Male; Pyrimidinones; Rifampin; Ritonavir; Tuberculosis | 2008 |